Navigation Links
Study Shows Metabolic Strategy of Stressed Cell

Major St. Jude Study of Changes in Gene Activity and Metabolic Enzymes Show How Cells Respond to a Sudden Decrease in the Levels of Coenzyme A, a Key Player in the Daily Biochemical Routines that Support Life

MEMPHIS, Tenn., March 23, 2007 /PRNewswire/ -- Investigators at St. Jude Children's Research Hospital have mapped out many of the dynamic genetic and biochemical changes that make up a cell's response to a shortage of a molecule called Coenzyme A (CoA), a key player in metabolism.

The results provide the most detailed look ever obtained of the complex metabolic changes in a cell triggered by a potentially fatal stress. CoA plays key roles in the cell's metabolism by participating in biochemical reactions in specific areas throughout the cell.

"The study provides the first detailed look at how the cell shifts genetic gears to respond to a significant change in its ability to carry on its daily metabolic chores," said Suzanne Jackowski, Ph.D., a member of the St. Jude Infectious Diseases department and the paper's senior author.

The St. Jude study is a significant contribution to the growing field of metabolomics -- the study of the molecules involved in metabolism, added Charles Rock, Ph.D., a member of the St. Jude Infectious Diseases department and co-author of the paper. Coupled with genetic studies of the cell, metabolomics is giving scientists a more detailed picture of how the body maintains its health in both normal environments and during times of stress, such as starvation or disease.

A report on this work appears in the March issue of "Chemistry and Biology."

The researchers studied the response to decreased CoA in a mouse model by blocking CoA production. Following the shutdown of CoA production, the cells quickly recycled CoA from other jobs so it could concentrate all its efforts on a single task: extracting life-supporting energy from nutrients in the mitocho ndria-the powerhouses of the cell.

"We identified the metabolic rearrangements the cell undergoes to ensure that the liver keeps CoA levels high enough to produce glucose and the cells of the body maintain enough free CoA for the mitochondria to keep producing ATP," said Yong-Mei Zhang, Ph.D., of the St. Jude Infectious Diseases department and first author of the report.

Other authors of this paper include Shigeru Chohnan (St. Jude), Kristopher G. Virga and Richard E. Lee (University of Tennessee Health Science Center, Memphis, Tenn.); Robert D. Stevens, Olga R. Ilkayeva, Brett R. Wenner, James R. Bain and Christopher B. Newgard (Duke University Medical Center, Durham, N.C.).

This work was supported in part by the National Institutes of Health, a Cancer Center (CORE) Grant and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit http://www.stjude.org.

CONTACT: Public relations, Carrie Strehlau, +1-901-495-2295 or, Summer Freeman, +1-901-495-3061 or, Scientific Communications, Marc Kusinitz, Ph.D.,+1-901-495-5020 or , all of St. Jude Children'sResearch Hospital carrie.strehlau@stjude.org summer.freeman@stjude.org marc.kusinitz@stjude.org

Web site: http://www.stjude.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... ... of the GlycoMark test throughout the Northeast U.S. , GlycoMark is the ... diabetes. The GlycoMark test provides a clinically proven one- to two-week measure of ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a leading ... Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, a ... of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and Vitamin ...
(Date:4/27/2017)... and DENVER (PRWEB) , ... April 27, 2017 ... ... Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement ... is enabled by the continuing support of the Jane and Leonard Korman Family ...
Breaking Medicine News(10 mins):